GIST CANCER RESEARCH FUND CO STUTMAN (EIN 134182988) - Form 990 Financial Analysis & Trantor Score

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2001

Legal Domicile

Principal Officer

ROBERT STUTMAN

Phone

8456346060

Tax Period

2024-08-01 to 2025-07-31

GIST CANCER RESEARCH FUND CO STUTMAN, founded in 2001, is a small nonprofit in the Diseases & Disorders sector that reported $364K in total revenue in fiscal year 2024. Revenue decreased 9% compared to the prior year. Expenses of $469K exceeded revenue, resulting in a 29% operating deficit.

Mission

THE ORGANIZATION'S PRIMARY FOCUS IS TO PROVIDE SUPPORT AND RESEARCH GRANTS FOR THE STUDY OF GASTRO-INTESTINAL STROMAL TUMORS

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $363,528

Program Service Revenue $0

Investment Income $0

Other Revenue $0

TOTAL REVENUE $363,528

Expense Breakdown

Grants Paid $450,000

Salaries & Benefits $0

Fundraising Expenses $4,852

Program Expenses $464,019

Other Expenses $18,871

TOTAL EXPENSES $468,871

Year-over-Year Comparison

	2024	2023	Change
Revenue	$363,528	$401,294	-0.1%
Expenses	$468,871	$603,773	-0.2%
Net Income	$-105,343	$-202,479	-0.5%

Key Indicators

✗ Grants to Organizations ✓ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✗ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

N/A

Employees

N/A

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Role	Reportable Comp	Other Comp	Total
ROBERT STUTMAN	Director	Director	$0	$0	$0
TANIA STUTMAN	Director	Director	$0	$0	$0
EPHRAIM CASPER	Director	Director	$0	$0	$0
PAMELA FEDOWICH	Director	Director	$0	$0	$0
JOHN LEONARD	Director	Director	$0	$0	$0
BRUCE TORREY	Director	Director	$0	$0	$0
WENDY KAPILOFF	Director	Director	$0	$0	$0
JULIE CRAMER	Director	Director	$0	$0	$0
WILLIAM PRICE	Director		$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$363,528	$468,871	$391,747	$-105,343
2024	$401,294	$603,773	$497,090	$-202,479
2023	$634,602	$477,154	$699,569	$157,448
2022	$500,625	$380,044	$542,121	$120,581
2021	$354,737	$386,347	$421,540	$-31,610
2020	$363,747	$313,490	$414,992	$50,257
2019	$377,838	$477,634	$364,735	$-99,796
2018	$417,829	$343,495	$464,532	$74,334

GIST CANCER RESEARCH FUND CO STUTMAN